Status:
COMPLETED
Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
Lead Sponsor:
GlaxoSmithKline
Conditions:
Rubella
Mumps
Eligibility:
All Genders
12-18 years
Phase:
PHASE4
Brief Summary
To evaluate the safety and immunogenicity of GSK Biologicals' live attenuated MMR vaccine (Priorix) in a local population in Singapore. The vaccine was administered as a single dose to healthy childre...
Eligibility Criteria
Inclusion
- A male or female infant between 12 and 18 months of age at the time of the vaccination
- Written informed consent obtained from the parents or guardians of the subject.
- Free of obvious health problems as established by medical history and clinical examination before entering into the study.
Exclusion
- Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the dose of study vaccine
- Previous vaccination against mumps and/or rubella
- History of, or intercurrent, measles, mumps, and/or rubella disease
- Known exposure to measles, mumps or rubella within 30 days prior to the start of the study
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
Key Trial Info
Start Date :
November 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2001
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00388440
Start Date
November 1 2000
End Date
April 1 2001
Last Update
September 20 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.